Easing Prior Authorization for GLP-1s

Few topics in health care are as contentious as prior authorization (PA) for glucagon-like peptide-1 (GLP-1) receptor agonists. Initially developed and approved to manage type 2 diabetes, GLP-1 medications such as semaglutide (e.g., Ozempic and Wegovy) and tirzepatide (e.g., Mounjaro and Zepbound) are now at the center of a massive shift in metabolic medicine, sparking a tug-of-war between clinical demand and insurance utilization management.

Evidence is mounting that GLP-1s are effective for treating several serious conditions beyond diabetes and obesity. Despite these benefits, insurers have implemented more rigorous PA protocols for GLP-1s than for other drugs due to their cost. The average price for brand-name semaglutide and tirzepatide is $900 to $1,500 per month before rebates.¹ For patients and physicians, the complexity of various payers' PA requirements is a critical hurdle to accessing therapies that are often life-changing.

This article seeks to demystify the PA process for GLP-1s, with time-saving EHR strategies and PA appeal principles that physicians can apply to other types of medications as well.

The Food and Drug Administration (FDA) evaluated the initial GLP-1 medications based on clinical trials that assessed them for treating type 2 diabetes or weight management. Insurance companies accordingly mapped the medical necessity guidelines that govern PA directly to specific FDA-approved indications. This resulted in two tracks.

Type 2 diabetes pathway. This PA track is exclusively for patients with a confirmed diagnosis of type 2 diabetes mellitus. Clinicians prescribing GLP-1 medications that are FDA-approved for this indication (e.g., Ozempic, Mounjaro, or Trulicity) generally find this process relatively straightforward, as long as the clinical chart contains concrete objective data. PA reviewers look for a documented baseline A1C of 6.5% or higher, a fasting plasma glucose level of at least 126 mg/dL, or a random glucose reading firmly in the diabetic range.

A frequent misstep in this pathway occurs when the prescriber only attaches a recent lab result. If a patient's blood glucose is well-controlled on other therapies, a recent A1C might fall below the 6.5% threshold, triggering an automatic denial. To prevent this, the documentation must explicitly include historical lab work that proves the initial diabetes diagnosis prior to starting therapy. Furthermore, insurers strictly enforce step therapy, usually mandating a 90-day “fail-first” trial of metformin, barring documentation of a clear contraindication such as advanced kidney disease (more on that later). Physicians must also verify that the patient is not taking a dipeptidyl peptidase 4 (DPP-4) inhibitor, because insurers will deny concurrent use due to overlapping mechanisms of action. Finally, this pathway is barred for patients with type 1 diabetes or latent autoimmune diabetes in adults. GLP-1s are not FDA-approved for these conditions, and getting insurance to pay for them “off-label” in such cases would likely require a formal appeals letter heavily backed by medical literature.